OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Satisfaction with Control of Mild to Moderate Atopic Dermatitis with Ruxolitinib Cream: US Physician and Patient Perspectives
Lawrence F. Eichenfield, J. Z. Liu, Simran Marwaha, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 3, pp. 685-696
Open Access | Times Cited: 4
Lawrence F. Eichenfield, J. Z. Liu, Simran Marwaha, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 3, pp. 685-696
Open Access | Times Cited: 4
Showing 4 citing articles:
Atopic Dermatitis Treatments Before and After Initiation of Ruxolitinib Cream: 6-Month Follow-Up Analysis of a US Payer Claims Database
J. Z. Liu, Karishma Desai, Chia‐Chen Teng, et al.
ClinicoEconomics and Outcomes Research (2025) Vol. Volume 17, pp. 69-77
Open Access
J. Z. Liu, Karishma Desai, Chia‐Chen Teng, et al.
ClinicoEconomics and Outcomes Research (2025) Vol. Volume 17, pp. 69-77
Open Access
JAK Inhibitors in Immune Regulation and Treatment of Vitiligo
Kewei Liu, Linyi Zhou, Meihui Shi, et al.
Cytokine & Growth Factor Reviews (2024) Vol. 80, pp. 87-96
Closed Access | Times Cited: 1
Kewei Liu, Linyi Zhou, Meihui Shi, et al.
Cytokine & Growth Factor Reviews (2024) Vol. 80, pp. 87-96
Closed Access | Times Cited: 1
The JAK1/JAK2 inhibitor ruxolitinib inhibits mediator release from human basophils and mast cells
Remo Poto, Leonardo Cristinziano, Gjada Criscuolo, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Remo Poto, Leonardo Cristinziano, Gjada Criscuolo, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Adverse event of ruxolitinib cream: a real-world analysis based on FDA adverse event reporting system from 2021 to 2024
Shi Zhou, Lei Li, Ling Jiang, et al.
Expert Opinion on Drug Safety (2024)
Closed Access
Shi Zhou, Lei Li, Ling Jiang, et al.
Expert Opinion on Drug Safety (2024)
Closed Access
